Systemic Therapy Management Strategies for Early-Stage Breast Cancer in Australia.

Area of Science:

• Oncology
• Medical Therapeutics
• Cancer Research

Background:

• Breast cancer is the most common cancer in Australian women, with early stages comprising most cases.
• Significant improvements in survival rates are attributed to advances in screening, diagnosis, and systemic therapies.

Purpose of the Study:

• To synthesize recent developments in systemic therapy for early breast cancer.
• To focus on Australian data and practice patterns for subtype-specific management.

Main Methods:

• Review of current literature and Australian practice patterns.
• Exploration of subtype-specific management strategies for ER+/HER2-, HER2+, and triple-negative breast cancer (TNBC).

Main Results:

• Discusses genomic assays (Oncotype DX, PAM50, MammaPrint) for ER+/HER2- breast cancer, role of CDK4/6 inhibitors, and extended endocrine therapy.
• Examines neoadjuvant therapy with dual HER2 blockade, cardiotoxicity-minimizing regimens, and antibody-drug conjugates for HER2-positive breast cancer.
• Reviews immunotherapy, dose-dense regimens, adjuvant capecitabine, and olaparib for BRCA-mutated TNBC.

Conclusions:

• Recent advances in systemic therapy offer improved outcomes for early breast cancer.
• Subtype-specific approaches, novel agents, and biomarker-driven strategies are shaping future treatment paradigms.
• Personalized medicine and treatment de-escalation are key future trends in early breast cancer management.